6th Feb 2020 13:45
(Alliance News) - Evgen Pharma PLC on Thursday said its collaboration with the University of Manchester has discovered a gene signature which could predict patient response to its SFX-01 medication when used to treat certain forms of breast cancer.
The drug development firm, which has a "long-standing" partnership with the university in the north west of England, said the gene signature can predict how patients with ER positive breast cancer react to being on the SFX drug.
ER positive breast cancer is a type of the disease which sees cancer cells grow in response to oestrogen hormone.
"This discovery yields further insight into the mechanism of action of SFX-01 and moves the company closer to determining which patients are most likely to respond favourably to treatment," Evgen said.
Chief Executive Steve Franklin added: "This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with potential partners."
Shares in Evgen were 5.3% lower at 4.50 pence each in London on Thursday afternoon.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L